GK
REGN icon

Graney & King’s Regeneron Pharmaceuticals REGN Stock Holding History

Graney & King’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.2K Hold
69
– – 0.02% 168
2026
Q1 		$53.4K Hold
69
– – 0.03% 138
2025
Q4 		$53.3K Buy
69
+68
+6,800% +$46.2K 0.03% 132
2025
Q3 		$565 Sell
1
-3
-75% -$1.7K ﹤0.01% 331
2025
Q2 		$2.1K Hold
4
– – ﹤0.01% 295
2025
Q1 		$2.54K Buy
4
+3
+300% +$2.06K ﹤0.01% 282
2024
Q4 		$712 Buy
+1
New +$839 ﹤0.01% 292

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Graney & King's REGN Position: Q2 2026 in Review

Graney & King held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 69 shares worth $43.2K. The position accounts for 0.02% of the portfolio, ranked #168.

Graney & King first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $53.4K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Graney & King held 69 shares of Regeneron Pharmaceuticals worth $43.2K as of Q2 2026.
  • Graney & King left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.02% of Graney & King's portfolio in Q2 2026, its #168 holding.
  • Graney & King first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Graney & King's Regeneron Pharmaceuticals position peaked at $53.4K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Graney & King's 13F filing for Q2 2026, filed 7 Aug 2026.